Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.64 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.64 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.64 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | PYGB | P11216 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18721346 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL17621600 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL7924751 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL13996793 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL1755358 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL14384932 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL16789213 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL7929801 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL6976489 | 1.00 | LGALS3 (0.64) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| SCHEMBL24115372 | 0.97 | LGALS1 (0.59) | LGALS3LGALS1LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230338270-A1 | COSMETIC COMPOSITION FOR SKIN IMPROVEMENT COMPRISING, AS ACTIVE INGREDIENTS, POLYSACCHARIDES, YEAST EXTRACT, AND STRAIN FERMENTATION PRODUCT WITH CHARACTERISTICS OF PROBIOTICS | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2023-10-26 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20180064650-A1 | SOLID PHARMACEUTICAL DOSAGE FORM SUITABLE FOR USE AS DRINKING WATER MEDICATION | UNIVERSITEIT GENT (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20170232040-A1 | Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same | TSETI IOULIA (GR) | 2017-08-17 | — | — | US | disclosed |
| US-20150329665-A1 | NOVEL HYDROPHILIC POLYMER FORM COMPRISING MALTODEXTRIN | LABORATOIRES URGO (FR) | 2015-11-19 | — | — | US | disclosed |
| US-8647613-B2 | Drug carrier | JCR PHARMACEUTICALS CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | LGALS3 4602/4885LGALS1 4764/4885LGALS9 4005/4885 |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | LGALS3 4571/4885LGALS1 4670/4885LGALS9 3805/4885 |
| US-20180064650-A1 | SOLID PHARMACEUTICAL DOSAGE FORM SUITABLE FOR USE AS DRINKING WATER MEDICATION | AQP1, SLCO1B1, SLCO1B3 | LGALS3 645/4885LGALS1 585/4885LGALS9 1290/4885 |
| US-20170232040-A1 | Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same | FECH, G6PD, G6PC1 | LGALS3 630/4885LGALS1 1071/4885LGALS9 2273/4885 |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | LGALS3 4602/4885LGALS1 4764/4885LGALS9 4005/4885 |
| US-20230338270-A1 | COSMETIC COMPOSITION FOR SKIN IMPROVEMENT COMPRISING, AS ACTIVE INGREDIENTS, POLYSACCHARIDES, YEAST EXTRACT, AND STRAIN FERMENTATION PRODUCT WITH CHARACTERISTICS OF PROBIOTICS | CUTA, SPOUT1, TYR | LGALS3 469/4885LGALS1 471/4885LGALS9 261/4885 |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | LGALS3 4571/4885LGALS1 4670/4885LGALS9 3805/4885 |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | LGALS3 4602/4885LGALS1 4764/4885LGALS9 4005/4885 |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | LGALS3 4602/4885LGALS1 4764/4885LGALS9 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.